The purpose of this study is to examine the effect of Andrographis Extract, Boesenbergia Extract compared to standard treatment in asymptomatic COVID patients.
Drug: Andrographis Paniculata
Andrographis extract, equivalent to andrographolide 20 mg per capsule, for a total of 180 mg of andrographolide per day, dosing into 3 capsules taking before meal for 3 times per day, for 5 days.
Drug: Boesenbergia
Boesenbergia extract, equivalent to pinostrobin 30 mg per capsule, for a total of 180 mg of pinostrobin per day, dosing into 2 capsules taking after meal for 3 times per day for 5 days.
Other: Standard supportive treatment
as recommended by guidelines from the Ministry of Public Health, Thailand. No antivirus was given.
Inclusion Criteria:
1. Age 18- 60 years old
2. Have been diagnosed as new COVID-19 case by RT-PCR since disease onset to admission
less than 7 days
3. Have asymptomatic infection assessed by the World Health Organization (WHO) disease
category
4. Do not have any of following disease or conditions
1. Body weight > 90 kg or BMI > 30 kg/m2
2. Hypertension that needs antihypertensive medication
3. Diabetes
4. Cardiovascular diseases including congenital heart disease
5. Cerebrovascular diseases
6. Chronic kidney and chronic liver diseases
7. COPD or chronic lung diseases
8. Lymphocyte <1,000 cells/mm3
9. Late-stage cancer
10. Auto-immune disease (e.g., SLE, Rheumatoid arthritis, multiple sclerosis, etc.)
or currently on immunosuppressive drug
11. Coagulation disorders or platelet disorders and are being treated with
anticoagulants such as warfarin, clopidogrel
12. Pregnancy
5. Willing to participate with the study and sign inform consents.
(Withdrawal criteria)
1. Patients withdraw from the study
2. Have severe adverse effect that may relate to Andographolide or Boesenbergia
Faculty of Medicine Ramathibodi Hospital
Ratchathewi, Bangkok, Thailand
Investigator: Pawin Numthavaj, MD
Contact: +6622011284
pawin.num@mahidol.ac.th
Pawin Numthavaj
+6622011284
pawin.num@mahidol.ac.th